SAM
ALXN

Storebrand Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Storebrand Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-87,133
Closed -$16M – 853
2021
Q2 		$16M Buy
87,133
+2,281
+3% +$392K 0.08% 299
2021
Q1 		$13M Buy
84,852
+8,007
+10% +$1.24M 0.07% 321
2020
Q4 		$12M Buy
76,845
+7,330
+11% +$942K 0.07% 310
2020
Q3 		$7.95M Sell
69,515
-4,332
-6% -$467K 0.06% 326
2020
Q2 		$8.29M Buy
73,847
+9,423
+15% +$1M 0.07% 291
2020
Q1 		$5.78M Buy
+64,424
New +$6.32M 0.06% 321

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Storebrand Asset Management's ALXN Position: Q3 2021 in Review

Storebrand Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 87,133 shares — an estimated $16M sold.

Storebrand Asset Management first reported a position in ALXN in Q1 2020 and held it in 6 quarters. The position peaked at $16M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Storebrand Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Storebrand Asset Management sold 87,133 Alexion Pharmaceuticals shares in Q3 2021, an estimated $16M.
  • Storebrand Asset Management first reported a position in Alexion Pharmaceuticals in Q1 2020 and held it in 6 quarters.
  • Storebrand Asset Management's Alexion Pharmaceuticals position peaked at $16M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Storebrand Asset Management's 13F filing for Q3 2021, filed 18 Jun 2026.